Brain diseases are one of the most socially and economically burdening diseases in
Europe. Among all brain diseases, more than 60% of social and economic costs are …

In the UK, the lifetime-documented prevalence of major depressive disorder (MDD) is
currently 10%. Despite its increasing prevalence and devastating impact on quality of life …

Background Conventional pharmacotherapies and psychotherapies for major depression
are associated with limited adherence to care and relatively low remission rates. Yoga may …

Approximately one-third of patients with major depressive disorder (MDD) have treatment-
resistant depression (TRD). The TRAL study will evaluate the prevalence and impact of TRD …

Background Seltorexant, a selective antagonist of human orexin-2 receptors, demonstrated
antidepressant effects in a previous exploratory study in patients with major depressive …

Therapeutic management of depression has currently important limitations, and its low
efficacy is reflected in high rates of non-response even after multiple trials of …

The goal of precision medicine (individually tailored treatments) is not being achieved for
neurobehavioural conditions such as psychiatric disorders. Traditional randomized clinical …

BACKGROUND: Although the clinical and health economic characteristics of commercially
insured adults with treatment-resistant depression (TRD) have been well characterized, little …

Background To investigate the risk of treatment-resistant depression (TRD) in patients with
depression by examining their clinical features, early prescription patterns, and early and …

Introduction While the psychiatric benefits of ketamine have been verified through clinical
trials, there is limited information about ketamine augmentation in patients with treatment …